INDIANAPOLIS, IN--(Marketwire - January 04, 2012) - Harlan Laboratories Inc., a leading contract research organization and research models and services company, announced today that Doug Vaughan has been recruited as Chief Financial Officer and David Broecker will join the company as President, Research Models & Services (RMS). Both will report to Hans Thunem, CEO of Harlan Laboratories, and be a part of the Management Committee.
"In spite of challenging pre-clinical markets, Harlan is experiencing growth that it intends to accelerate in the coming years. Our activities over the past 12 months have been aimed at becoming an even stronger player in the pre-clinical segment and to improve the overall quality of our products and services. Doug and David both bring tremendous depth and experience in working with customers and other stakeholders and will be instrumental to those plans," said Thunem.
Vaughan is an experienced global finance executive, across multiple industries and business models. His industry experience includes chemicals, petroleum, aerospace, consumer products, diversified industrial, distribution and services. Most recently, Vaughan served as vice president of finance for Ingersoll Rand in the consumer products industry. Prior to that, Vaughan served as chief financial officer for International Specialty Products, a privately held $1.7 billion global specialty chemical company. His experience also includes 14 years with Honeywell International (formerly AlliedSignal) in successively larger roles encompassing controllership, sourcing, procurement, pricing and contracts, acquisitions and finance.
"I'm thrilled to have the opportunity to join Harlan as its CFO at this exciting time. I look forward to helping define and execute the company's strategic growth plans and to building a world class finance capability to support the company's growth. Personally, I feel this position is the perfect culmination of my background in different industries and my experience in senior finance and operational leadership roles," said Vaughan.
Broecker is an experienced biopharmaceutical executive with a track record of successfully transforming organizations. Most recently, he was the CEO of BioCritica, a private biotechnology company focused on the development and commercialization of products for the critical care market. From 2001 to 2009, Broecker was a senior executive at Alkermes, including the last three as president and CEO. During his tenure, he led the strategic transformation of Alkermes from a partner-driven, drug-delivery company to an integrated biopharmaceutical company with the capabilities to develop and commercialize proprietary products.
Broecker began his career with Eli Lilly and Company, serving in a variety of commercial leadership positions where he formulated development strategies and launched several new products in the pharmaceutical and medical device areas. In addition, he held significant leadership positions in development and operations including general management assignments in Germany and Ireland.
"I am very excited about the opportunity to join Harlan and lead the RMS group. The market for research products and services is undergoing tremendous changes driven by improvements in science and evolution in the way research and development is done by pharmaceutical, biotechnology and medical device companies. Harlan has the capabilities and customer relationships to grow and continue to be a major industry player," said Broecker.
Vaughan has a Bachelor of Science in chemical engineering from the University of Connecticut, an MBA from the University of Virginia and is a certified Six Sigma Green Belt. Doug will be based in Harlan's Corporate Office in Indianapolis.
Broecker has an MBA from the University of Chicago, a Master of Science in chemical engineering from the Massachusetts Institute of Technology (MIT) and a Bachelor of Arts from Wabash College. A native of Indiana, David will also be based in Harlan's Corporate Office in Indianapolis.